Bone Mineral Density Loss in People With Epilepsy Taking Valproate as a Monotherapy: A Systematic Review and Meta-Analysis
Objective: Data on changes in bone mineral density (BMD) from valproate (VPA) therapy are ambiguous and conflicting. Thus, the aim of this study was to systematically review the existing data and carry out a meta-analysis to investigate the effect of VPA as a monotherapy on BMD in people with epilep...
Main Authors: | Rui Zhong, Qingling Chen, Xinyue Zhang, Mengmeng Li, Jianmin Liang, Weihong Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-11-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.01171/full |
Similar Items
-
Valproate-coenzyme A conjugate blocks opening of receptor binding domains in the spike trimer of SARS-CoV-2 through an allosteric mechanism
by: Federica Maschietto, et al.
Published: (2023-01-01) -
Relationship between Bone Density and Biochemical Markers of Bone among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd
by: Abolghasem Rahimdel, et al.
Published: (2016-11-01) -
Hematological Side Effects of Valproate Used for the Treatment of Epilepsy
by: Pınar YILMAZBAŞ, et al.
Published: (2021-04-01) -
Valproate associated brain volume‐loss in pediatric epilepsy—A case series
by: Johanna Umlauf, et al.
Published: (2023-12-01) -
Hyperammonemia in patients receiving valproic acid in the hospital setting: A retrospective review
by: Tressa McMorris, PharmD, BCPS, et al.
Published: (2021-07-01)